Compare RGP & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | MCRB |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.8M | 139.7M |
| IPO Year | 2006 | 2015 |
| Metric | RGP | MCRB |
|---|---|---|
| Price | $4.27 | $13.46 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | $6.00 | ★ $14.33 |
| AVG Volume (30 Days) | ★ 517.2K | 53.8K |
| Earning Date | 01-07-2026 | 03-12-2026 |
| Dividend Yield | ★ 6.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | ★ $506,739,000.00 | $351,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | ★ N/A | $21.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.13 | $6.53 |
| 52 Week High | $8.43 | $29.98 |
| Indicator | RGP | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 38.80 | 35.54 |
| Support Level | $4.19 | $12.99 |
| Resistance Level | $4.75 | $16.12 |
| Average True Range (ATR) | 0.21 | 0.93 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 14.41 | 13.44 |
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.